Proportion of Direct Acting Oral Anticoagulants (DOACs) not prescribed as edoxaban by all Sub-ICB Locations
Why it matters: In January 2022 the NHS in England announced a national procurement programme for DOACs, which states:
- For patients commencing treatment for AF: subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use edoxaban where this is clinically appropriate. If edoxaban is contraindicated or not clinically appropriate for the specific patient then, subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should then consider rivaroxaban first, then apixaban or dabigatran.
- For patients already prescribed a DOAC for the treatment of AF: subject to the criteria specified in the relevant NICE technology appraisal guidance, commissioners may wish to consider developing local policy to review patients currently prescribed apixaban, rivaroxaban or dabigatran, where clinically appropriate.
The NHS England National Medicines Optimisation Opportunities for 2023/24
identify using best value direct-acting oral anticoagulants as an area for improvement.
Please note: OpenPrescribing.net measures also have a consistent way of visualising measures, where 'lower is better' and therefore in this case we show the proportion of DOACs which are NOT prescribed as edoxaban.
Description: Percentage DOACs items not prescribed as edoxaban
National medicines optimisation opportunities
(or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six
months. Each chart shows the results for the individual Sub-ICB Location,
plus deciles across all Sub-ICB Locations in the
NHS in England.
View measure for NHS England combined →
Do you need help with your analysis? Don't forget to check the FAQ page
, and get in touch
if you have questions.